Tuberculosis Control: Challenges of an Ancient and Ongoing Epidemic

Comstock GW . Field trials of tuberculosis vaccines: how could we have done them better? Control Clin Trials 1994; 15:247–76.

Aronson JD Aronson CF Taylor HC . A twenty-year appraisal of BCG vaccination in the control of tuberculosis. AMA Arch Intern Med 1958; 101:881–93.

Schatz A Waksman SA . Effect of streptomycin and other antibiotic substances upon Mycobacterium tuberculosis and related organisms. Proc Soc Expt Biol and Med 1944; 57:244–8.

Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948; 2:769–82.

Lehman J . Para-amino salicylic acid in the treatment of pulmonary tuberculosis. Lancet 1946; 1:15–6.

Daniel TM . Captain of death: the story of tuberculosis. Rochester (NY): University of Rochester Press; 1997. p. 217–20.

Tuberculosis Chemotherapy Centre. A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India. Bull World Health Org 1959; 21:51–144.

Medical Research Council. Treatment of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid: a Medical Research Council investigation. Br Med J 1950; 2:1073–85.

Iseman MD . Tuberculosis therapy: past, present and future. Eur Respir J Suppl 2002; 36:87S–94S.

Doster B Murray FJ Newman R Woolpert SF . Ethambutol in the initial treatment of pulmonary tuberculosis. U.S. Public Health Service tuberculosis therapy trials. Am Rev Respir Dis 1973; 107:177–90.

Fox W Ellard GA Mitchison DA . Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3(10 Suppl 2):S231–79.

Grosset J . The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tuberc 1978; 53:5–12.

Hong Kong Chest Service, British Medical Research Council. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Tubercle 1982; 63:89–98.

Lincoln EM . The effect of antimicrobial therapy on the prognosis of primary tuberculosis in children. Am Rev Tuberc 1954; 69:682–9.

Ferebee SH . Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970; 26:28–106.

American Thoracic Society. Chemoprophylaxis for the prevention of tuberculosis: a statement by an Ad Hoc Committee. Am Rev Respir Dis 1967; 96:558–60.

Garibaldi RA Drusin RE Ferebee SH Gregg MB . Isoniazid-associated hepatitis: report of an outbreak. Am Rev Respir Dis 1972; 106:357–65.

American Thoracic Society/Center for Disease Control and Prevention (US). Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161(4 Pt 2):S221–47.

Navin TR McNabb SJ Crawford JT . The continued threat of tuberculosis. Emerg Infect Dis 2002; 8:1187.

Murray CJ Styblo K Rouillon A . Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis 1990; 65:6–24.

Dye C Scheele S Dolin P Pathania V Raviglione MC . Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282:677–86.

Selwyn PA Hartel D Lewis VA Schoenbaum EE Vermund SH Klein RS . A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545–50.

Daley CL Small PM Schecter GF Schoolnik GK McAdam RA Jacobs WR . An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326:231–5.

Wendel KA Sterling TR . Tuberculosis and HIV. AIDS Clin Care 2002; 14:9–15.

Cantwell MF Snider DE Jr Cauthen GM Onorato IM . Epidemiology of tuberculosis in the United States, 1985 through 1992 JAMA 1994;272:535–9.

CDC (US). Tuberculosis morbidity among U.S.-born and foreign-born populations—United States, 2000. MMWR Morb Mortal Wkly Rep 2002;51(5):101–4.

Hadzibegovic DS Maloney SA Cookson ST Oladele A . Determining TB rates and TB case burden for refugees. Int J Tuberc Lung Dis 2005; 9:409–14.

Frieden TR Sterling T Pablos-Mendez A Kilburn JO Cauthen GM Dooley SW . The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328:521–6.

Pablos-Mendez A Knirsch CA Barr RG Lerner BH Frieden TR . Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med 1997; 102:164–70.

Moore M Onorato IM McCray E Castro KG . Trends in drug-resistant tuberculosis in the United States, 1993-1996. JAMA 1997; 278:833–7.

World Health Organization. Antituberculosis drug resistance in the world. Report no. 2: prevalence and trends. Geneva: World Health Organization; 2000. WHO/CDS/TB/2000.278.

Zaza S Blumberg HM Beck-Sague C Haas WH Woodley CL Pineda M . Nosocomial transmission of Mycobacterium tuberculosis: role of health care workers in outbreak propagation. J Infect Dis 1995; 172:1542–9.

Chaulk CP Moore-Rice K Rizzo R Chaisson RE . Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995; 274:945–51.

American Thoracic Society; CDC (US); Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52(RR-11):1–77.

Chan ED Laurel V Strand MJ Chan JF Huynh ML Goble M . Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103–9.

Granich RM Oh P Lewis B Porco TC Flood J . Multidrug resistance among persons with tuberculosis in California, 1994-2003. JAMA 2005; 293:2732–9.

Recommendations for prevention and control of tuberculosis among foreign-born persons. Report of the Working Group on Tuberculosis Among Foreign-Born Persons. MMWR Recomm Rep 1998; 47(RR-16):1–29.

Binkin NJ Zuber PL Wells CD Tipple MA Castro KG . Overseas screening for tuberculosis in immigrants and refugees in the United States: current status. Clin Infect Dis 1996; 23:1226–32.

DeRiemer K Chin DP Schecter GF Reingold AL . Tuberculosis among immigrants and refugees. Arch Intern Med 1998; 158:753–60.

Wells CD Zuber PL Nolan CM Binkin NJ Goldberg SV . Tuberculosis prevention among foreign-born persons in Seattle-King County, Washington. Am J Respir Dis Crit Care Med 1997; 156:573–7.

Dasgupta K Menzies D . Cost-effectiveness of tuberculosis control strategies among immigrants and refugees. Eur Respir J 2005; 25:1107–16.

Goldberg SV Wallace J Jackson JC Chaulk CP Nolan CM . Cultural case management of latent tuberculosis infection. Int J Tuberc Lung Dis 2004; 8:76–82.

World Health Organization. An expanded DOTS framework for effective tuberculosis control. Geneva: World Health Organization; 2002. WHO/CDS/TB/2002.297.

World Health Organization. Treatment of tuberculosis: guidelines for national programmes. Geneva: World Health Organization; 2003. WHO/CDS/TB/2003.313.

World Health Organization. Tuberculosis [cited 2007 Jun 4]. Available from: URL: http://www.who.int/mediacentre/factsheets/fs104/en

Kim JY Mukherjee JS Rich ML Mate K Bayona J Becerra MC . From multidrug-resistant tuberculosis to DOTS expansion and beyond: making the most of a paradigm shift. Tuberculosis (Edinb) 2003; 83:59–65.

Mitnick C Bayona J Palacios E Shin S Furin J Alcantara F . Community-based therapy for multidrug resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348:119–28.

Stop TB Working Group on DOTS-Plus for MDR-TB. A prioritized research agenda for DOTS-Plus for multidrug resistant tuberculosis (MDR-TB). Int J Tuberc Lung Dis 2003; 7:410–4.

Gupta R Kim JY Espinal MA Caudron JM Pecoul B Farmer PE . Public health. Responding to market failures in tuberculosis. Science 2001; 293:1049–51.

Notice to readers: revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 2006; 55(43):1176.

De Cock KM Chaisson RE . Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis 1999; 3:457–65.

Bucher HC Griffith LE Guyatt GH Sudre P Naef M Sendi P . Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999; 13:501–7.

Hiransuthikul N Nelson KE Hiransuthikul P Vorayingyong A Paewplot R . INH preventive therapy among adult HIV-infected patients in Thailand. Int J Tuberc Lung Dis 2005; 9:270–5.

Grant AD Charalambous S Fielding KL Day JH Corbett EL Chaisson RE . Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA 2005; 293:2719–25.

McNabb SJ Braden CR Navin TR . DNA fingerprinting of Mycobacterium tuberculosis: lessons learned and implications for the future. Emerg Infect Dis 2002; 8:1314–9.

Northrup JM Miller AC Nardell E Sharnprapai S Etkind S Driscoll J . Estimated costs of false laboratory diagnoses of tuberculosis in three patients. Emerg Infect Dis 2002; 8:1264–70.

Small PM Hopewell PC Singh SP Paz A Parsonnet J Ruston DC . The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med 1994; 330:1703–9.

Moore DF Guzman JA Mikhail LT . Reduction in turnaround time for laboratory diagnosis of pulmonary tuberculosis by routine use of a nucleic acid amplification test. Diagn Microbiol Infect Dis 2005; 52:247–54.

Noordhoek GT Mulder S Wallace P van Loon AM . Multicentre quality control study for detection of Mycobacterium tuberculosis in clinical samples by nucleic amplification methods. Clin Microbiol Infect 2004; 10:295–301.

Kambashi B Mbulo G McNerney R Tembwe R Kambashi A Tihon V . Utility of nucleic acid amplification techniques for the diagnosis of pulmonary tuberculosis in sub-Saharan Africa. Int J Tuberc Lung Dis 2001; 5:364–9.

Mazurek GH Jereb J Lobue P Iademarco MF Netchock B Vernon A . Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54(RR-15):49–55.

Pai M Riley LW Colford JM Jr . Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004; 4:761–76.

Barnes PF . Weighing gold or counting spots: which is more sensitive to diagnose latent tuberculosis infection? Am J Respir Crit Care Med 2006; 174:731–2.

O'Brien RJ Spigelman M . New drugs for tuberculosis: current status and future prospects. Clin Chest Med 2005; 26:327–40.

Munsiff SS Kambili C Ahuja SD . Rifapentine for the treatment of pulmonary tuberculosis. Clin Infect Dis 2006; 43:1468–75.

Fortun J Martin-Davila P Navas E Perez-Elias MJ Cobo J Tato M . Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005; 56:180–5.

Andries K Verhasselt P Guillemont J Gohlmann HW Neefs JM Winkler H . A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307:223–7.

Lenaerts AJ Gruppo V Marietta KS Johnson CM Driscoll DK Tompkins NM . Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005; 49:2294–301.

Friedrich MJ . Basic science guides design of new TB vaccine candidates. JAMA 2005; 293:2703–5.

Fruth U Young D . Prospects for new TB vaccines: Stop TB Working Group on TB Vaccine Development. Int J Tuberc Lung Dis 2004; 8:151–5.

McShane H Pathan AA Sander CR Goonetilleke NP Fletcher HA Hill AV . Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) 2005; 85:47–52.

TB Alliance Portfolio: Nitroimidazole PA-824. June 2007 [cited 2007 Jun 4]. Available from: URL: http://72.3.224.152/new/portfolio/html-portfolio-item.php?id=18

World Health Organization. Fifty-third World Health Assembly: Stop Tuberculosis initiative. Report by the Director-General. A53/5; 5 May 2000. Geneva: World Health Organization; 2000.

Dye C Watt CJ Bleed DM Hosseini SM Raviglione MC . Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 2005; 293:2767–75.